Loading organizations...
Key people at Respirix.
Respirix develops digital health software and hardware, including a point-of-care monitoring device. This technology offers proprietary, non-invasive insights into the pulmonary vasculature, specifically designed for monitoring conditions such as congestive heart failure. The integrated system analyzes key cardiovascular parameters to deliver actionable data for improved patient management.
The company was founded in 2015 by Daniel Burnett and Evan Luxon. They established Respirix based on the insight that non-invasive cardiovascular health monitoring could significantly enhance patient care. Their aim was to develop novel technological solutions for pulmonary and cardiac conditions, building an innovative diagnostic and monitoring platform.
Respirix targets healthcare providers and patients benefiting from continuous, non-invasive cardiac and pulmonary monitoring. The company's vision centers on improving patient outcomes through earlier detection and better management of cardiovascular diseases. They aim to make advanced physiological insights accessible, thereby supporting proactive health and treatment decisions.
Key people at Respirix.
Respirix is a San Francisco–based medtech startup building a non‑invasive, point‑of‑care cardiopulmonary monitoring device (Cardiospire) and accompanying software to detect early signs of congestive heart failure (CHF) decompensation and related pulmonary problems before patients become symptomatic[1][3].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech & Healthcare Landscape
Quick Take & Future Outlook
If you’d like, I can:- Pull the most recent patent filings and summarize technical claims (useful to understand their sensing approach)[2][1].[2][1]- Summarize publicly available clinical or validation data and regulatory status.